1739. A Novel Anti Gram-Positive Antibiotic Class Acting on a Non-Essential Target
Session: Symposium: New Approaches Circumventing Classical Drug Targets
Sunday, October 26, 2008: 12:00 AM
Room: Room 202B
Heike Brotz-Oesterhelt, PhD, AiCuris GmbH & Co., Wuppertal, Germany and  H. Brotz-Oesterhelt, None.

Curriculum Vitae: Heike Brötz-Oesterhelt
Affiliation: AiCuris GmbH & Co.KG
Friedrich-Ebert-Str. 475 / Geb. 302
D-42117 WUPPERTAL
Phone: +49 202 3 176 3 1300; Fax: +49 202 3 176 3 1600
email: heike.broetz-oesterhelt@aicuris.com
Studies, Academic Degrees, Professional Background:
1987 - 1993: studied Chemistry and Biology; earned Diploma in Biology
1993 - 1997: specialized in Microbiology; PhD in Microbiology
1998 - 2003: Senior scientist, laboratory leader, project manager, Bayer HealthCare, Wuppertal
2004 - 2006: Biological Coordinator of Exploratory Antibacterial Research, Bayer HealthCare
2006 - date: Head of Antibacterial Research, AiCuris GmbH & Co.KG, Wuppertal
2007: Habilitation and Venia legendi for Pharmaceutical Microbiology, University of Bonn
Awards and Honours:
1992 Grant of the "Studienstiftung des deutschen Volkes”
1998 GEFRUB Prize of the University of Bonn for one of the best PhD theses in 1998
1998 Award of the German Association for General and Applied Microbiology for one of the best microbiological PhD thesis in 1998
2003 Invited Lecture at the Gordon Research Conference on Staphylococcal Diseases, Oxford, U.K
2004 Research Innovation Prize of the Bayer HealthCare AG
2006 Clinical Research and Development Publication Award, Pfizer Inc.
2006 Invited Lecture at the International Conference on Staphylococci and Staphylococcal Infections, Maastricht, NL
2007 Invited Lecture at the Gordon Research Conference on Staphylococcal Diseases, Les Diablerets, Switzerland
2007 Member of the advisory board, Network of Excellence EURO-Pathogenomics
Current Research Interests:
- antibacterial drug discovery, evaluation of antibacterial potential and general compound
profiles in vitro and in vivo
- mode of action studies on novel antibiotics
- bacterial proteome analysis
- biochemistry of the gram-positive cell wall and its inhibition by antibiotics
Academic and Research Appointments
since 2003: Lectures and tutorials on bacterial resistance and antibacterial drug discovery for students of biology, medicine and pharmacy at the University of Bonn
Selected recent publications
1) Brötz-Oesterhelt, H. and Nina A. Brunner: How many modes of action should an antibiotic have? Curr. Opin. Pharmacol. (in press).
2) Beyer, D., Kroll, H.-P., Brötz-Oesterhelt, H. Methods to assay inhibitors of tRNA synthetase activity. New antibiotic targets. In: Methods in Molecular Medicine. Vol. 142, S. Champney (Ed.), Humana Press, 53-61.
3) Hinzen, B., Raddatz, S., Paulsen, H., Lampe, T., Schumacher, A., Häbich, D., Hellwig, V., Benet-Buchholz, J., Endermann, R., Labischinski, H., Brötz-Oesterhelt, H. (2006). Medicinal chemistry optimization of acyldepsipeptides of the class of enopeptin antibiotics. Chem. Med. Chem. 1, 689-693.
4) Labischinski, H., Freiberg, C., Brötz-Oesterhelt, H. (2005). New Antibiotics. In: Pathogenomics - Genome analysis of pathogenic microbes. J. Hacker and U. Dobrindt (Eds.), Wiley VCH, 505-531.
5) Brötz-Oesterhelt, H., Beyer, D., Kroll, H.-P., Endermann, R., Ladel, C., Schroeder, W., Hinzen, B., Raddatz, S., Paulsen, H., Henninger, K., Bandow, J. E., Sahl, H.-G., Labischinski, H. (2005). Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nature Medicine. 11, 1082-1087.
6) Freiberg, C., Brötz-Oesterhelt, H. (2005). Functional genomics in antibacterial drug discovery. Drug Discov.Today. 10, 927-935.
7) Brötz-Oesterhelt H., Bandow, J. E., Labischinski, H. (2005). Bacterial proteomics and its role in antibacterial drug discovery. Mass. Spec. Rev. 24, 549-565.
8) Freiberg, C., B



<< Previous Presentation | Next Presentation